title: Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study.
abstract: OBJECTIVE
  The impact of statins on glucose metabolism and adipokines remains controversial. We compared the effects of rosuvastatin and atorvastatin on glucose homeostasis, insulin sensitivity (IS), adiponectin and leptin levels as well as systemic inflammation in non-diabetic patients with dyslipidaemia.
  
  
  METHODS
  Thirty-six patients were randomly assigned to 10 mg/day of rosuvastatin (n = 18) or 20 mg/day of atorvastatin (n = 18) for 12 weeks. Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, triglycerides (TG), fasting plasma glucose, insulin, homeostasis model assessment-insulin resistance (HOMA-IR), quantitative IS check index (QUICKI), adiponectin, leptin and high-sensitivity C-reactive protein (hsCRP) were measured at baseline and after 4 and 12 weeks.
  
  
  RESULTS
  Both statins significantly lowered TC, LDL-C, non-HDL-C and TG compared with baseline. Only rosuvastatin caused a significant reduction in insulin and HOMA-IR levels (-35%, p = 0.005 and -33%, p = 0.011 respectively) and a significant increase in QUICKI (+11%, p = 0.003) at 12 weeks. In terms of adipokines and hsCRP, no difference was observed after 4 and 12 weeks of treatment with either statin.
  
  
  CONCLUSIONS
  Rosuvastatin compared with atorvastatin resulted in significant improvements in IS indices. No significant changes in adiponectin, leptin or hsCRP levels were observed at 4 and 12 weeks of treatment with either statin.
authors.affiliation: Endocrinology Clinic, Hippokration Hospital, Thessaloniki, Greece. anagnwstis.pan@yahoo.gr
authors.forename: P
authors.initials: P
authors.lastname: Anagnostis
authors.forename: D
authors.initials: D
authors.lastname: Selalmatzidou
authors.forename: S A
authors.initials: SA
authors.lastname: Polyzos
authors.forename: A
authors.initials: A
authors.lastname: Panagiotou
authors.forename: A
authors.initials: A
authors.lastname: Slavakis
authors.forename: A
authors.initials: A
authors.lastname: Panagiotidou
authors.forename: V G
authors.initials: VG
authors.lastname: Athyros
authors.forename: A
authors.initials: A
authors.lastname: Karagiannis
authors.forename: D P
authors.initials: DP
authors.lastname: Mikhailidis
authors.forename: M
authors.initials: M
authors.lastname: Kita
mesh_terms: D054392:Adipokines / Q000378:metabolism*; D000368:Aged; D000069059:Atorvastatin; D001786:Blood Glucose / Q000378:metabolism*; D002784:Cholesterol / Q000378:metabolism; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D008875:Middle Aged; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D014280:Triglycerides / Q000378:metabolism
chemical_list: D054392:Adipokines; D001786:Blood Glucose; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007328:Insulin; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D014280:Triglycerides; D000068718:Rosuvastatin Calcium; D002784:Cholesterol; D000069059:Atorvastatin